The Preimplantation Genetic Testing Market Is Expected To Reach $1.2 Billion | MarketsandMarkets.

Chicago, Dec. 18, 2023 (GLOBE NEWSWIRE) — Preimplantation Genetic Testing market in terms of revenue is estimated to be worth $0.7 Billion in 2023 and is poised to reach $1.2 billion in 2028, growing at a CAGR of 11.4% from 2023 to 2028 according to a latest report published by MarketsandMarkets. The growth of this market is mainly driven by the increasing number of fertility clinics worldwide, and advances in genetic analysis technology. However, high procedural costs associated with preimplantation genetic testing may restrain the growth of the market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605

Preimplantation Genetic Testing market Scope:

Report Coverage Details
Market Revenue in 2023 $0.7 Billion
Estimated Value in 2028 $1.2 Billion
Growth Rate Set to grow at a CAGR of 11.4%
Market Size Available for 20212028
Prediction Time 20232028
Units of Prediction Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments covered Process Type, Technology, Product, Application, Cycle Type, and End User
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Report Highlights Updated financial information / product portfolio of players
Key Market Opportunities Use of fertility treatment options by single parents and same-sex couples
Key Market Drivers Decrease in fertility rate

On the basis of method type, the preimplantation genetic testing market is segmented into preimplantation genetic screening and preimplantation genetic diagnosis. The preimplantation genetic screening segment accounts for the largest share of the preimplantation genetic testing market. A large part of this share can be attributed to factors such as greater awareness and acceptance of genetic screening methods among prospective parents and increasing maternal age.

Based on technology, the preimplantation genetic testing market is segmented into PCR, NGS, FISH, CGH, and SNP segments. The next-generation sequencing segment is expected to dominate the preimplantation genetic testing market with falling sequencing prices, rapidly increasing penetration of NGS in diagnostics, and increasing use of these systems in fertility clinics and research institutes for preimplantation. genetic diagnosis and preimplantation genetic screening.

On the basis of product and service, the preimplantation genetic diagnosis and screening market is segmented into instruments, reagents & consumables, and software and services. By 2022, the reagents and consumables segment dominates this market. A large part of this share can be attributed to the increasing number of preimplantation genetic diagnoses and preimplantation genetic screening procedures performed worldwide.

On the basis of region, the global preimplantation genetic testing market is categorized into North America, Europe, Asia-Pacific, and the RoW segments. North America will hold the largest market share in 2022 due to increasing government funding for genetic testing, and declining fertility rates. Other factors driving the demand for the North American market include increasing infertility among women in the US due to the growing prevalence of polycystic ovary syndrome (PCOS), the increasing incidence of reproductive disorders such as of chlamydia, and increasing age at first pregnancy.

Buy Preimplantation Genetic Testing Industry Report (245 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=605

Preimplantation Genetic Testing market major players covered in the report, such as:

  • Illumina, Inc. (US)
  • Thermo Fisher Scientific Inc. (US)
  • Agilent Technologies, Inc. (US)
  • Revvity (US)
  • The Cooper Companies, Inc. (US)
  • Abbott (USA)
  • Takara Bio Inc. (Japan)
  • Qiagen (Germany)
  • Vitrolife (Sweden)
  • Oxford Nanopore Technologies Plc (UK)
  • Oxford Gene Technology IP Limited (UK)
  • Yikon Genomics (China)
  • Shiva Scientific Company (India)
  • Nanjing Superyears Gene Technology Co. Ltd. (China)
  • Medicover Genetics (Germany)
  • Medgenome (India)
  • Fulgent Genetics (US)
  • Invicta Genetics (Poland)
  • Genea Limited (Australia)
  • Scigene Corporation (US)
  • Bioarray SL (Spain)
  • Unimed Biotech (Shanghai) Co. Ltd. (China)
  • Genemind Biosciences Co. Ltd. (China)
  • Berry Genomics (China)
  • Bangkok Genomics Innovation (Thailand)
  • and Among Others

Request a FREE Sample Page: https://www.marketsandmarkets.com/requestsampleNew.asp?id=605

This research report classifies the preimplantation genetic testing market into the following segments and subsegments:

Regional Division

  • North America
  • Europe
  • Asia Pacific
  • Rest in the World

Method Type Split

  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis

Technology Sharing

  • Next Generation Sequence
  • Polymerase Chain Reaction
  • Fluorescence In Situ Hybridization
  • Comparative Genomic Hybridization
  • Single-Nucleotide Polymorphism

Product Segmentation

  • Reagents and Consumables
  • Instruments
  • Software and Services

Division of Application

  • Aneuploidy
  • Structural Chromosomal Abnormalities
  • Single Gene Disorder
  • X-Linked Disorder
  • HLA typing
  • Gender Recognition

Type of Cycle Split

  • Fresh Non-Donor
  • Frozen Non-Donor
  • New Donor
  • Frozen Donor

End user Split

  • Fertility Clinics
  • Hospitals
  • Diagnostic Laboratories
  • Other End Users

Get 10% Free Customization of this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=605

Preimplantation Genetic Testing Industry Recent Developments:

  • In 2023, Thermo Fisher Scientific Inc. (US) launched two new NGS-based test kits to support preimplantation genetic testing-aneuploidy (PGT-A), which is commonly used in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.
  • In 2022, The Cooper Companies, Inc. released (US) the addition of Parental QC, Genetic PN check, and Origin of Aneuploidy to PGT-A testing as PGT-Complete.
  • In 2021, Vitrolife (Sweden) acquired Igenomix (Spain), a leader in reproductive genetic testing services especially for IVF clinics.

Key Market Stakeholders:

  • Senior Management
  • End User
  • Finance/Purchasing Department
  • R&D Department

Reporting Objective:

  • To define, describe, segment, and forecast the global preimplantation genetic testing market by method type, technology, product, application, cycle type, end user, and region.
  • To provide detailed information about major factors influencing market growth (such as drivers, restraints, opportunities, and challenges).
  • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the overall Preimplantation Test Market.
  • To analyze market opportunities for stakeholders and provide details on the competitive landscape for key players.
  • To forecast the size of the market shares with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World.
  • To profile key players and comprehensively analyze their product portfolios, market position, and core competencies.
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within a wide range of business categories and product excellence.

Related Reports:

Ultrasound Market

Digital PCR (dPCR) and Real-time PCR (qPCR) Market

Next Generation Sequencing (NGS) Market

In Vitro Fertilization Market

Infertility Treatment Market

Research Perspective: https://www.marketsandmarkets.com/ResearchInsight/preimplantation-genetic-testing-market.asp

Content source: https://www.marketsandmarkets.com/PressReleases/preimplantation-genetic-testing.asp

            

#Preimplantation #Genetic #Testing #Market #Expected #Reach #Billion #MarketsandMarkets
Image Source : www.globenewswire.com

Leave a Comment